Showing results (51-60 of 195) with videos related to
Sort By:
Pageof 20
Annals of the Royal College of Surgeons of England|October 4, 2012
Interactions in the aetiology, presentation and management of synchronous and metachronous adenocarcinoma of the prostate and rectumG F Nash, K J Turner, T Hickish, et al.The British Journal of Radiology|April 1, 1983
The role of computed tomography in the detection of bone metastases in breast cancer patientsJ Muindi, R C Coombes, S Golding, et al.Lancet (London, England)|March 20, 1976
Breast-cancer osteolysis, bone metastases, and anti-osteolytic effect of aspirinT J Powles, M Dowsett, G C Easty, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1986
Immunocytochemical assay for estrogen receptor in patients with breast cancer: relationship to a biochemical assay and to outcome of therapyR A McClelland, U Berger, L S Miller, et al.Cancer Chemotherapy and Pharmacology|January 1, 1983
Danazol treatment for advanced breast cancerR C Coombes, D Perez, J C Gazet, et al.British Journal of Cancer|November 1, 1994
Phase I study of mitozantrone, methotrexate and mitomycin with granulocyte colony-stimulating factor (filgrastim) in patients with advanced breast cancerM E O'Brien, M Nicolson, A Montes, et al.Prostaglandins|March 1, 1976
Human breast tumour-induced osteolysis and prostaglandinsM Dowsett, G C Easty, T J Powles, et al.Journal of Steroid Biochemistry|January 1, 1989
Lack of diurnal variation in plasma levels of androstenedione, testosterone, estrone and estradiol in postmenopausal womenP E Lønning, M Dowsett, S Jacobs, et al.European Journal of Cancer (Oxford, England : 1990)|September 1, 1995
Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumoursP A Ellis, A Norman, A Hill, et al.Cancer Chemotherapy and Pharmacology|June 10, 1998
Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patientsP Beale, I Judson, J Hanwell, et al.Pageof 20